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To the Editor: We greatly appreciate the large study of Wolf
et al.1 pointing a link between low serum 25-OH vitamin D
levels and early mortality among incident hemodialysis
patients who did not beneficiate of active vitamin D.
The inverse link between higher all-cause mortality and
lower 25-OH vitamin D levels in these patients strongly
suggests that vitamin D deficiency is a mortality risk factor
that may be reversed by its correction. Unfortunately, the fact
that the patients who eventually received 1aOH vitamin D
were previously better treated (with higher arteriovenous
fistula prevalence and at lower risk (lower heart failure
prevalence)) skews the evidence that the survival benefit was
only due to active vitamin D administration. Therefore, it is
interesting to recall that the risk of cancer was significantly
reduced by native vitamin D increasing serum 25-OH
vitamin D above 80 nmol/l (by a placebo-controlled rando-
mized trial performed in post-menopausal patients in whom
50 cases of new cancer was observed).2 Therefore, we suggest
that newer 1aOH vitamin D derivatives survival benefit
should be proven by a placebo-controlled trial in patients
with 25-OH vitamin D levels X70 nmol/l as recommended
by the National Kidney Foundation-Kidney Disease Out-
comes Quality Initiative (NKF-K/DOQI) for the CKD grades
3–4 patients.
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We thank the authors for their comments regarding
deficiency of 25-hydroxyvitamin D (25D) as a novel risk
factor for mortality.1 Although we attempted to adjust for
baseline factors at the initiation of dialysis including
certain quality of care indicators such as fistula prevalence,
we agree with the authors that residual confounding
remains a limitation in this and other observational
studies. We also agree with the authors that the benefits
of maintaining normal 25D levels observed in other
clinical settings such as cancer prevention lend further
evidence in support of the importance of the vitamin D
axis in health.
We do recommend caution, however, when attempting
to infer the relative importance of 25D versus calcitriol
(1,25D) deficiency based on our study. Although it is
tempting to conclude that 25D deficiency is more
important than 1,25D deficiency given that the greatest
risk of mortality was observed in the group with the lowest
25D levels, it is important to recognize that virtually all
patients in this study were profoundly 1,25D deficient.
Thus, the group of patients with severe 25D deficiency also
had severe 1,25D deficiency: they were globally deficient in
the vitamin D axis.
Although we strongly agree with the suggestion that
randomized controlled trials are needed to test the benefits
of active vitamin D preparations on survival in patients
with kidney disease, we also believe that trials are needed
to test the effects of correction of 25D deficiency either
alone or in combination with active vitamin D.
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To the Editor: Levin et al.1 have documented that serum
calcitriol decrease with glomerular filtration rate decline is
independent of calcidiol. As low calcitriol is associated with
coronary calcification, they speculate that hypocalcitriolemia
favors vascular calcification and hyperparathyroidism, and
propose to perform randomized trial with activated vitamin
D against placebo, but not against ergocalciferol, because,
according to their citation of our cohort study,2 vitamin D2
would not effectively suppress parathyroid hormone.
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